

## Biosimilarity: The FDA Perspective

Table 2.3 (Continued) Potential U.S. Biosimilar Candidates through 2024

<b>Brand</b>	<b>Generic Name</b>	<b>Therapeutic Category</b>	<b>Worldwide Annual Sales (2015) (\$millions)</b>	<b>Patent Expiry</b>
Intron A	Interferon alfa-2b	Oncology and immunomodulators	120	Dec 2020
Simulect	Basiliximab	Oncology and immunomodulators	112	Dec 2020
Soliris	Eculizumab	Blood	2,613	Mar 2021
Myalept	Metreleptin	Endocrine	10	Mar 2021
Mircera	Methoxy polyethylene glycol-epoetin beta	Blood	265	Nov 2021
Cimzia	Certolizumab pegol	Musculoskeletal	1,161	Dec 2021
Entyvio	Vedolizumab	Gastrointestinal	438	Dec 2021
Cyramza	Ramucirumab	Oncology and immunomodulators	347	Dec 2021
Jetrea	Ocriplasmin	Sensory organs	26	Dec 2021
NovoThirteen	Catridecacog	Blood	23	Dec 2021
Nplate	Romiplostim	Blood	508	Jan 2022
Natpara	Parathyroid hormone	Endocrine	26	Jun 2022
V419	DTP; hepatitis B, hemophilus influenza type b, and polio vaccine	Systemic antiinfectives	12	Jun 2022
Simponi	Golimumab	Musculoskeletal	1,358	Jul 2022
Vpriv	Velaglycerase alfa	Various	370	Jul 2022
Zaltrap	Ziv-aflibercept	Oncology and immunomodulators	109	Jul 2022
Obizur	Susoctocog alfa	Blood	6	Jul 2022
Tanzeum	Albiglutide	Endocrine	118	Dec 2022
Actimmune	Interferon gamma-1b	Oncology and immunomodulators	102	Dec 2022
Ixiaro	Japanese encephalitis vaccine	Systemic antiinfectives	48	Dec 2022
Apidra	Insulin glulisine recombinant	Endocrine	437	Jan 2023
Myozyme	Alglucosidase alfa	Various	670	Feb 2023
Nulojix	Belatacept	Oncology and immunomodulators	66	Apr 2023
Imvamune	Smallpox vaccine	Systemic antiinfectives	8	May 2023
Kineret	Anakinra	Musculoskeletal	83	Jul 2023
Stelara	Ustekinumab	Oncology and immunomodulators	2,504	Sep 2023
Victoza	Liraglutide (rDNA origin)	Endocrine	2,516	Dec 2023

(Continued)